Replimune reports 36% ORR in anti-PD1 failed melanoma; enters Roche collaboration for RP2/3

Replimune Group, Inc.

Collaboration with Roche to develop RP3 with atezolizumab/bevacizumab in 3L CRC and 1L/2L HCC; cost sharing; Phase 2 start H1 2023.
IGNYTE anti-PD1 failed melanoma: 36% ORR, 20% CR rate in first 75 patients; 85% of responses ongoing; systemic activity seen.
RP2/3 update: uveal melanoma 28.6% ORR (4/14 evaluable); soft tissue sarcoma 3/5 responding; responses durable.
Phase 2 plans for RP2/3: SCCHN (130 patients), HCC (60), CRC (60); enrollment in H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.